blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3996813

EP3996813 - PHENYL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  13.01.2023
Database last updated on 15.06.2024
FormerRequest for examination was made
Status updated on  15.04.2022
FormerThe international publication has been made
Status updated on  18.01.2021
Formerunknown
Status updated on  13.08.2020
Most recent event   Tooltip13.01.2023Application deemed to be withdrawnpublished on 15.02.2023  [2023/07]
Applicant(s)For all designated states
Cura Therapeutics, LLC
505 Coast Blvd South, Suite 302
La Jolla, CA 92037 / US
[2022/19]
Inventor(s)01 / DEWJI, Nazneen
3405 Stadium Place
San Diego, CA 92122 / US
 [2022/19]
Representative(s)Jones Day
Rechtsanwälte, Attorneys-at-Law, Patentanwälte
Prinzregentenstrasse 11
80538 München / DE
[2022/19]
Application number, filing date20750944.910.07.2020
[2022/20]
WO2020US41497
Priority number, dateUS201962873137P11.07.2019         Original published format: US 201962873137 P
[2022/19]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2021007474
Date:14.01.2021
Language:EN
[2021/02]
Type: A1 Application with search report 
No.:EP3996813
Date:18.05.2022
Language:EN
The application published by WIPO in one of the EPO official languages on 14.01.2021 takes the place of the publication of the European patent application.
[2022/20]
Search report(s)International search report - published on:EP14.01.2021
ClassificationIPC:A61P25/00, A61P25/16, A61P25/28, A61P27/02, A61K31/18, A61K31/63
[2022/19]
CPC:
A61P25/00 (EP); C07C311/21 (EP,US); A61P25/16 (EP);
A61P25/28 (EP); A61P27/02 (EP); C07C2601/14 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/19]
TitleGerman:PHENYLVERBINDUNGEN UND PHARMAZEUTISCHE ZUSAMMENSETZUNGEN DAVON SOWIE DEREN THERAPEUTISCHE ANWENDUNGEN[2022/19]
English:PHENYL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS[2022/19]
French:COMPOSÉS DE PHÉNYLE ET COMPOSITIONS PHARMACEUTIQUES ASSOCIÉES, ET LEURS APPLICATIONS THÉRAPEUTIQUES[2022/19]
Entry into regional phase05.01.2022National basic fee paid 
05.01.2022Designation fee(s) paid 
05.01.2022Examination fee paid 
Examination procedure05.01.2022Examination requested  [2022/20]
05.01.2022Date on which the examining division has become responsible
30.08.2022Application deemed to be withdrawn, date of legal effect  [2023/07]
22.09.2022Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time  [2023/07]
22.09.2022Despatch of communication of loss of particular rights: Claims {1}
Fees paidRenewal fee
18.07.2022Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[X]US3954994  (HOLLAND GERALD F, et al) [X] 1-4,21,22,36-56 * tables *; columns 18-43 * * examples I-XVI * * claims 1-10 *;
 [X]WO9936398  (LILLY CO ELI [GB], et al) [X] 1,3,4,6-10,12,13,36-38,40-42,47-52,58-73 * abstract * * page 9, line 11 - page 11, line 24 * * example 5 * * claims 1-10 *;
 [Y]WO0050391  (MERCK & CO INC [US], et al) [Y] 1-81 * examples 1-636 * * claims 1-26 *;
 [Y]WO2004033418  (ACTELION PHARMACEUTICALS LTD [CH], et al) [Y] 1-81 * abstract * * examples 1-209 * * claims 1-22 *;
 [Y]WO2005026134  (NOVARTIS AG [CH], et al) [Y] 1-81 * abstract * * last full paragraph *; page 2 * * compounds *; pages 17-21 * * page 38, paragraph 4 - page 40, paragraph 1 * * examples 1-9 * * claims 1-31 *;
 [X]WO2005085189  (MEDICAL RES COUNCIL [GB], et al) [X] 1,3-5,23-25,27,32,33,36,39,41,47-52,58-72,75,76,79 * abstract * * page 72; table 1; compounds 1a-1f * * claims 1-49 *;
 [Y]JP2006160752  (NEUROTECH CO LTD) [Y] 1-81 * abstract * * scheme *; page 9 * * claim 1 *;
 [X]WO2007071443  (NOVARTIS AG [CH], et al) [X] 1,23-25,27,32,33,36,37,39-41,47-52,58-74 * abstract * * page 18, line 12 - page 19, line 7 * * table *; pages 52-56; compounds 6, 9, 10, 15, 24-29 * * claims 1-16 *;
 [X]JP2008308493  (KISSEI PHARMACEUTICAL) [X] 1,3,23,34-38,40,41,43-48,50,52,58-64,73 * abstract * * page 32; compounds 12-46 * * page 48; compounds 2-4 * * claims 1-9 *;
 [X]US2012094964  (INOUE TADASHI [JP], et al) [X] 1-13,36-45,47-56,58-63 * examples 56, 81-83 * * examples 110-126 * * claims 1-11 *;
 [X]US9416101  (ORTON DARREN [US]) [X] 1-3,6-9,12-14,19,20,36-38,40-45,47-55 * abstract * * columns 85-87 * * examples 1-64 * * claims 1-7 *;
 [X]WO2017011323  (UNIV MARYLAND [US]) [X] 1,3,4,23-26,36-41,47-52,58-63 * abstract * * compounds *; pages 86-98 * * tables *; pages 168-177 * * table *; page 184 * * compounds *; pages 185-196 * * claims 1-21 *;
 [X]WO2017160069  (MEDICINAL BIOCONVERGENCE RES CT [KR], et al) [X] 1,3,4,23-25,27,32,33,36-38,40,41,47-52,58-73 * abstract * * table *; pages 30-60; compounds 2,37,38,40,47,49,57,84,146,155,226,233 * * claims 1-15 *;
 [X]CN109293537  (UNIV CHINA PHARMA) [X] 1-3,6-9,12,14,19,20,36-38,40-43,47-53 * page 7; compounds III-2 *;
 [X]CN109651208  (SHANGHAI INST MATERIA MEDICA CAS) [X] 1,3,6-9,12,14,19,20,36-38,40,41,43,47-52,58-73 * abstract * * compounds *; pages 14-16 * * examples 59, 85 * * claims 1-10 *;
 [IP]WO2019139869  (CURA THERAPEUTICS LLC [US]) [IP] 1-81 * abstract * * pages 47-48 * * examples 1-4 ** claims 1-82 *;
 [X]  - MAURIZIO PULICI ET AL, "Optimization of Diarylthiazole B-Raf Inhibitors: Identification of a Compound Endowed with High Oral Antitumor Activity, Mitigated hERG Inhibition, and Low Paradoxical Effect", CHEMMEDCHEM, DE, (20141127), vol. 10, no. 2, doi:10.1002/cmdc.201402424, ISSN 1860-7179, pages 276 - 295, XP055730245 [X] 1,2,4,23-26,36-39,41-43,47-53 * page 277; compound 22 *

DOI:   http://dx.doi.org/10.1002/cmdc.201402424
 [X]  - NIRMAL PAHADI ET AL, "Catalytic Intermolecular Hydroamination of Vinyl Ethers", SYNLETT, DE, (20091021), vol. 2009, no. 19, doi:10.1055/s-0029-1218293, ISSN 0936-5214, pages 3135 - 3138, XP055730250 [X] 1,3,23-26,36-38,40,41,47-52 * page 3136; table 1; compound 3j *

DOI:   http://dx.doi.org/10.1055/s-0029-1218293
 [X]  - ZHOU YANG ET AL, "Synthesis and biological evaluation of novel (E)-N'-(2,3-dihydro-1H-inden-1-ylidene) benzohydrazides as potent LSD1 inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, (20150620), vol. 26, no. 18, doi:10.1016/J.BMCL.2015.06.054, ISSN 0960-894X, pages 4552 - 4557, XP029695096 [X] 1,4,6-8,10,12-14,19,20,36-38,40-42,47-52 * scheme 2 *; page 4554; compounds 2, 3 * * page 45554; table 2; compounds 6d, 6e, 6k, 6l *

DOI:   http://dx.doi.org/10.1016/j.bmcl.2015.06.054
 [X]  - HANKE THOMAS ET AL, "Synthesis and pharmacological characterization of benzenesulfonamides as dual species inhibitors of human and murine mPGES-1", BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER, NL, (20131016), vol. 21, no. 24, doi:10.1016/J.BMC.2013.10.006, ISSN 0968-0896, pages 7874 - 7883, XP028796474 [X] 1,3,6-9,12,13,36-38,40,41,47-52,58-63 * abstract * * page 7877; table 2; compounds 11, 14, 15 *

DOI:   http://dx.doi.org/10.1016/j.bmc.2013.10.006
by applicantUS3536809
 US3598123
 US3845770
 US3916899
 US4008719
 US4328245
 US4409239
 US4410545
 US5033252
 US5052558
 US5059595
 US5073543
 US5120548
 US5323907
 US5354556
 US5591767
 US5612059
 US5639476
 US5639480
 US5674533
 US5698220
 US5709874
 US5733566
 US5739108
 US5759542
 US5798119
 US5840674
 US5891474
 US5900252
 US5922356
 US5972891
 US5972366
 US5980945
 US5985307
 US5993855
 US6004534
 US6039975
 US6045830
 US6048736
 US6060082
 US6071495
 US6087324
 US6113943
 US6120751
 US6131570
 US6139865
 US6197350
 US6248363
 US6253872
 US6264970
 US6267981
 US6271359
 US6274552
 US6316652
 US6350458
 WO0217918
 US6376461
 US6419961
 US6589548
 US6613358
 US6699500
    - BALLARD et al., Lancet, (20110000), vol. 377, pages 1019 - 1031
    - KUMARWALTER, Aging, (20110000), vol. 3, pages 803 - 812
    - MASTERS et al., Nat. Rev. Dis. Primers, (20150000), vol. 1, page 15056
    - FRIGERIOSTROOPER, Annu. Rev. Neurosci., (20160000), vol. 39, pages 57 - 79
    - ISRAEL et al., Nature, (20120000), vol. 482, pages 216 - 220
    - BERGE et al., J. Pharm. Sci., (19770000), vol. 66, pages 1 - 19
    - HARPER, Progress in Drug Research, (19620000), vol. 4, pages 221 - 294
    - GANGWAR et al., Des. Biopharm. Prop. Prodrugs Analogs, (19770000), pages 409 - 421
    - BUNDGAARD, Controlled Drug Delivery, (19870000), vol. 17, pages 179 - 96
    - FLEISHER et al., Methods Enzymol., (19850000), vol. 112, pages 360 - 381
    - WANG et al., Curr. Pharm. Design, (19990000), vol. 5, pages 265 - 287
    - PAULETTI et al., Adv. Drug. Delivery Rev., (19970000), vol. 27, pages 235 - 256
    - MIZEN et al., Pharm. Biotech., (19980000), vol. 11, pages 345 - 365
    - GAIGNAULT et al., Pract. Med. Chem., (19960000), pages 671 - 696
    - VERMA et al., Drug Development and Industrial Pharmacy, (20000000), vol. 26, pages 695 - 708
    - BALANT et al., Eur. J. DrugMetab. Pharmacokinet., (19900000), vol. 15, pages 143 - 53
    - BALIMANESINKO, Adv. Drug Delivery Rev., (19990000), vol. 39, pages 117 - 151
    - BROWNE, Clin. Neuropharmacol., (19970000), vol. 20, pages 1 - 12
    - BUNDGAARD, Arch. Pharm. Chem., (19790000), vol. 86, pages 1 - 39
    - BUNDGAARD, Adv. Drug Delivery Rev., (19920000), vol. 8, pages 1 - 38
    - SINHABABUTHAKKER, Adv. Drug Delivery Rev., (19960000), vol. 19, pages 131 - 148
    - FARQUHAR et al., J. Pharm. Sci., (19830000), vol. 72, pages 324 - 325
    - FREEMAN et al., J. Chem. Soc., Chem. Commun., (19910000), pages 875 - 877
    - FRIISBUNDGAARD, Eur. J. Pharm. Sci., (19960000), vol. 4, pages 49 - 59
    - NATHWANIWOOD, Drugs, (19930000), vol. 45, pages 866 - 94
    - STELLA et al., Drugs, (19850000), vol. 29, pages 455 - 73
    - VALENTINOBORCHARDT, Drug Discovery Today, (19970000), vol. 2, pages 148 - 155
    - WALLER et al., Br. J. Clin. Pharmac., (19890000), vol. 28, pages 497 - 507
    - TAKADA, Encyclopedia of Controlled Drug Delivery, Wiley, (19990000), vol. 2
    - SANTUSBAKER, J. Controlled Release, (19950000), vol. 35, pages 1 - 21
    - VERMA et al., J. Controlled Release, (20020000), vol. 79, pages 7 - 27
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.